Loading…

Loading grant details…

Active H2020 European Commission

Plasma epigenomics: A new liquid biopsy paradigm

€2.96M EUR

Funder European Commission
Recipient Organization The Hebrew University of Jerusalem
Country Israel
Start Date Aug 01, 2021
End Date Jul 31, 2026
Duration 1,825 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101019560
Grant Description

Genomic DNA is packaged by histone proteins that carry a multitude of post-translational modifications, which reflect cellular transcriptional states. When cells die, fragmented chromatin retaining histone modifications is released to the circulation.

Recently, we pioneered chromatin immunoprecipitation of cell-free nucleosomes carrying active chromatin marks followed by sequencing (cfChIP-seq).

Our results show that cfChIP-seq provides multidimensional epigenetic information and that the plasma epigenome contains rich information about the identity and the transcriptional state of the originating cells.

Liquid biopsies already entered the clinical practice, yet current methodologies use them to assess genetic information.

Our breakthrough methodology opens an unprecedented opportunity to delineate the transcriptional state of specific cell types and different pathologic states. Here we aim to translate plasma epigenomic information into medically relevant findings.

The challenge is recovering the states of the cells represented in the circulation and relate these to pathological processes.

Our working hypothesis is that this task is attainable by probabilistic modeling exploiting knowledge about epigenomics and transcription programs in health and disease.

In this project we will assay plasma samples from multiple patient and donor cohorts to characterize the relation between tissue gene expression and circulating chromatin profiles, to recover the immune system status and chart how it changes with disease progression and response to treatment, and to monitor transplant patients for early detection of rejection.

Our extensive preliminary data, our expertise in probabilistic modeling and genomics and our collaborators’ access to relevant patient cohorts support the projects’ feasibility.

Plasma epigenomics will open a new non-invasive window into tissue dynamics in living humans, beyond current liquid biopsy technologies, with far-reaching medical implications.

All Grantees

The Hebrew University of Jerusalem

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant